PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Dobiasch, S.* ; Kampfer, S.* ; Burkhardt, R. ; Schilling, D. ; Schmid, T.E. ; Wilkens, J.J. ; Combs, S.E.

BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid fiducial marker.

BioXmark für die Hochpräzisionsstrahlentherapie im orthotopen Pankreastumor-Mausmodell: Erfahrungen mit einem liquiden Marker.

Strahlenther. Onkol. 193, 1039-1047 (2017)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background and purpose: High-precision radiotherapy (RT) requires precise positioning, particularly with high single doses. Fiducial markers in combination with onboard imaging are excellent tools to support this. The purpose of this study is to establish a pancreatic cancer mouse model for high-precision image-guided RT (IGRT) using the liquid fiducial marker BioXmark (Nanovi, Kongens Lyngby, Denmark). Methods: In an animal-based cancer model, different volumes of BioXmark (10–50 µl), application forms, and imaging modalities—cone-beam computer tomography (CBCT) incorporated in either the Small Animal Radiation Research Platform (SARRP) or the small-animal micro-CT Scanner (SkyScan; Bruker, Brussels, Belgium)—as well as subsequent RT with the SARRP system were analyzed to derive recommendations for BioXmark. Results: Even small volumes (10 µl) of BioXmark could be detected by CBCT (SARRP and Skyscan). Larger volumes (50 µl) led to hardening artefacts. The position of BioXmark was monitored at least weekly by CBCT and was stable over 4 months. BioXmark was shown to be well tolerated; no changes in physical condition or toxic side effects were observed in comparison to control mice. BioXmark enabled an exact fusion with the original treatment plan with less hardening artefacts, and minimized the application o f contrast agent for fractionated RT. Conclusion: An orthotopic pancreatic tumor mouse model was established for high-precision IGRT using a fiducial marker. BioXmark was successfully tested and provides the perfect basis for improved imaging in high-precision RT. BioXmark enables a unique application method and optimal targeted precision in fractionated RT. Therefore, preclinical trials evaluating novel fractionation regimens and/or combination treatment with high-end RT can be performed.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.735
0.992
9
11
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cone-beam Computed Tomography ; Dose Fractionation ; Models, Animal ; Pancreatic Neoplasms ; Radiotherapy, Image-guided; Radiation-therapy; Neoadjuvant Chemoradiation; Cancer; Ultrasound; Placement; Motion
Sprache englisch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 0179-7158
e-ISSN 1439-099X
Zeitschrift Strahlentherapie und Onkologie : Journal of Radiation Oncology, Biology, Physics
Quellenangaben Band: 193, Heft: 12, Seiten: 1039-1047 Artikelnummer: , Supplement: ,
Verlag Urban & Vogel
Verlagsort Heidelberg
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
PubMed ID 28808749
DOI 10.1007/s00066-017-1193-y
WOS ID WOS:000415946000006
Scopus ID 85028551797
Erfassungsdatum 2017-09-22
[➜Korrektur melden]